175 related articles for article (PubMed ID: 15998901)
21. Breast cancer (non-metastatic).
Rodger A; Stebbing J; Thompson AM
Clin Evid; 2006 Jun; (15):2360-92. PubMed ID: 16973090
[No Abstract] [Full Text] [Related]
22. [Current adjuvant endocrine treatment of breast cancer].
Dedes KJ; Gabriel N; Fink D
Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
[TBL] [Abstract][Full Text] [Related]
23. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Koeberle D; Thuerlimann B
Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant endocrine therapy for locally advanced breast cancer.
Ma CX; Ellis MJ
Semin Oncol; 2006 Dec; 33(6):650-6. PubMed ID: 17145344
[TBL] [Abstract][Full Text] [Related]
25. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Dickler M
Nat Clin Pract Oncol; 2005 Oct; 2(10):498-9. PubMed ID: 16205767
[No Abstract] [Full Text] [Related]
26. Tamoxifen in breast cancer: not so easy to write off.
Munshi A; Singh P
Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
28. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
Ryan PD; Goss PE
Nat Clin Pract Oncol; 2005 Dec; 2(12):596-7. PubMed ID: 16341095
[No Abstract] [Full Text] [Related]
29. Neo-adjuvant hormonal therapy.
Valenzuela M; Julian TB
Breast J; 2008; 14(3):279-83. PubMed ID: 18373643
[TBL] [Abstract][Full Text] [Related]
30. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
31. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
[TBL] [Abstract][Full Text] [Related]
33. Tumoristatic action of tamoxifen: experimental evidence for clinical application in stage I and II breast cancer.
Jordan VC
J Chemother; 1989 Jul; 1(4 Suppl):1144-7. PubMed ID: 16312810
[No Abstract] [Full Text] [Related]
34. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
35. 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Akashi-Tanaka S; Shimizu C; Ando M; Shibata T; Katsumata N; Kouno T; Terada K; Shien T; Yoshida M; Hojo T; Kinoshita T; Fujiwara Y; Yoshimura K
Breast; 2009 Jun; 18(3):171-4. PubMed ID: 19410462
[TBL] [Abstract][Full Text] [Related]
36. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Ingle JN
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
[TBL] [Abstract][Full Text] [Related]
38. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
39. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
